Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19
‘Modest’ increase in heart attack hospitalization rates after years of decline
12 July 2021Delta surge forces fresh virus restrictions as England embraces ‘Freedom Day’
13 July 2021Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19
NOR-Solidarity, an independent, add-on, randomized controlled trial to the World Health Organization (WHO) Solidarity trial, found that neither remdesivir nor hydroxychloroquine (HCQ) affected viral clearance in hospitalized patients with COVID-19. The WHO Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality but did not assess antiviral effects of these drugs. The findings are published in Annals of Internal Medicine.
